Facebook
X
LinkedIn
ForwardCardiovascular APP Practice Update
Focusing on new and emerging antihypertensive therapies to help PAs/NPs understand indications, mechanisms, and integration into treatment algorithms for more effective BP control. Providing detailed updates on PCSK9 inhibitors and novel lipid therapies, emphasizing patient selection, clinical outcome data, and practical use in cases of statin intolerance, severe dyslipidemia, and persistent ASCVD risk. Reviewing evidence-based GDMT for both HFrEF and HFpEF, including titration strategies, sequencing, combination therapy, and overcoming barriers to achieving target doses. Highlighting emerging valvular heart disease procedures (e.g. transcatheter mitral and tricuspid interventions) to improve recognition of candidates for referral and understanding of peri-procedural management. Using case-based and guideline-aligned content to ensure learners can translate the latest evidence into consistent, high-quality clinical practice.
Target Audience
- Physician Associates
- Nurse Practitioners
- Advanced practice providers
Learning Objectives
- Review the AHA/ACC 2025 guidelines for hypertension management, causes of resistant hypertension, and novel device-based therapies, including renal denervation.
- Identify statin intolerance and alternative lipid management strategies, including available PCSK9 inhibitors: alirocumab, evolocumab, and inclisiran.
- Discuss guideline-directed medical therapy for heart failure with preserved and reduced ejection fraction. The following drug classes will be discussed in detail: beta blocker (metoprolol, carvedilol, bisoprolol), ACE/ARB/ARNI (including lisinopril, losartan, and entresto), MRA (spironolactone, eplerenone), and SGLT2 (dapagliflozin and empagliflozin).
- Explain the percutaneous interventional options for aortic, mitral, and tricuspid valve pathologies.
12:45-1:00 Welcome
Laura Lu, APNP
1:00-1:30 Novel Approaches to Resistant Hypertension Management
This activity will review the AHA/ACC 2025 guidelines for hypertension management, causes of resistant hypertension, and novel device-based therapies including renal denervation.
1:30-1:45-q&a session
Steven Sawyer, MD
1:45-2:00 Novel Lipid Therapies
This activity will review statin intolerance and alternative lipid management strategies, including available PCSK9 inhibitors: alirocumab, evolocumab, and inclisiran.
2:15-2:30 -q&a session
Zachary Pape, PharmD
2:30-3:00 GDMT for HFrEF and HFpEF
This activity will review guideline directed medical therapy for heart failure with preserved and reduced ejection fraction. The following drug classes will be discussed in detail: beta blocker (metoprolol, carvedilol, bisoprolol), ACE/ARB/ARNI (including lisinopril, losartan, and entresto), MRA (spironolactone, eplerenone), and SGLT2 (dapagliflozin and empagliflozin).
3:00-3:15 q&a session
Jessica Jackson, APNP & Rachel Betthauser, APNP
3:15-3:45 Valvular Heart Disease and Interventional Therapies
This activity will review the percutaneous interventional options for aortic, mitral, and tricuspid valve pathologies.
3:45-4:00 q&a session
Jeremiah Depta, MD
In accordance with the ACCME® Standards for Integrity and Independence in Accredited Continuing Education, Standard 3, all persons in control of content must disclose any relevant financial relationships. It is the policy of the Medical College of Wisconsin to identify, mitigate and disclose the absence or presence of all relevant financial relationships with ineligible companies held by the speakers/presenters, authors, planners, and other persons who may influence content of this accredited continuing education. The following in control of content had no relevant financial relationships to disclose.
- Laura Lu, APNP
- Zachary Pape, PharmD
- Stephen Sawyer, MD
- Rachel Betthauser, APNP
- James F. Kleczka, MD
- Maria Diener
The following persons in control of content disclosed the following financial relationships which were reviewed via the MCW conflict of interest mitigation process and addressed:
Name | Company | Role |
Jessica Jackson, APNP | CVRx - Barostim | Speaker |
Jeremiah Depta, MD | Edwards lifesciences Boston Scientific | Consultant |
AANP Credit Designation Statement
The Medical College of Wisconsin is approved as a provider of nurse practitioner continuing education by the American Associated of Nurse Practitioners: AANP Provider Number 150930. This program has been approved for 3.00 contact hours of continuing education (which includes 1.50 hours of pharmacology).
Physician Associate Accreditation Statement
This activity has been reviewed by the American Academy of Physician Associates Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 3 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation. Approval is valid from 3/5/2026 to 3/5/2026. AAPA reference number: CME-2014953.
Available Credit
- 1.50 NP PharmacologyNP Pharmacology credit.
- 3.00 NP Contact Hours
- 3.00 PAPA credit.
Price
HOW TO REGISTER:
Register at https://ocpe.mcw.edu. Select "Login" in the upper right corner and follow the prompts to log in to your existing account or create a new account. Then, select Cardiovascular APP Practice Update under “Featured Courses,” select "Register", and follow the prompts.